Healthy volunteers test new reversal agent in Early-Stage trial
Knowledge-focused
Completed
This early-stage study tested the safety of a new drug called BB-025 in 72 healthy adults. Some participants received BB-025 alone, while others got it after another drug, BB-031. The goal was to see if BB-025 is safe and how the body processes it, not to treat any disease.
Phase: PHASE1 • Sponsor: Basking Biosciences, Inc. • Aim: Knowledge-focused
Last updated May 17, 2026 04:08 UTC